ITM Power’s MSCI Debut Adds Urgency to a Month Already Packed with Catalysts

ITM Power stock surges 400% ahead of MSCI entry and £46.5m grant decision. Analysts split: targets 60p-200p. UK subsidy ruling on May 26 is key catalyst.

May is shaping up to be an unusually decisive period for ITM Power. The electrolyser maker enters the MSCI UK Small Cap Index on May 29, a mechanical event that forces passive funds to buy the stock regardless of valuation. That institutional tailwind arrives just days after the UK subsidy authority rules on a £46.5m grant that could unlock the company’s next-generation Chronos production line — and the stock has already surged 160% since January.

The rally, which now stretches to a 400% gain over twelve months, has been fuelled by operational progress rather than hype. A strategic alliance with global engineering group Worley triggered a spike in trading volumes to 13.2m shares — 168% above the daily average — and pushed the share price to 174.80p. Worley plans to embed ITM’s Neptune V electrolyser into medium-scale hydrogen projects, opening a direct channel into external project pipelines. That complements ITM’s existing strategy through its Berlin-based subsidiary Hydropulse, which builds, owns and operates decentralised green hydrogen plants under long-term offtake contracts.

The numbers behind the narrative have improved markedly. For the first half of fiscal 2026, ITM posted record revenues of £18m and lifted its full-year forecast to between £40m and £43m. The order book now stands at £152m, with 71% of contracts classified as profitable — a stark shift from the loss-making legacy deals that weighed on the business. That still leaves a long road to profitability: the pre-tax loss widened to £45.4m in the year to April 2025, compared with £27.1m a year earlier. Jefferies does not expect EBITDA breakeven before 2028.

Analysts are deeply split on valuation. Jefferies raised its price target from 115p to 200p, citing higher revenue visibility and lower cost of capital. The bank sees revenues of £56m in 2027 and £71m in 2028. But even Jefferies warns of an asymmetric risk profile: the downside scenario implies a 52% share price loss, while the upside potential is a more modest 37%. UBS, by contrast, keeps its target at 60p and rates the stock neutral, arguing the shares trade on a price-to-sales ratio of roughly 38 — far too rich for the fundamentals.

Morgan Stanley is the most bullish of the three, forecasting £169m in revenue for fiscal 2028, 54% above consensus. It is the first positive note the bank has issued on a hydrogen equipment supplier since 2021. The divergence underscores just how wide the range of outcomes remains.

The next major catalyst lands on May 26, when the UK subsidy body publishes its assessment of a £46.5m grant application for the Chronos production line. If the decision is favourable, management intends to take a final investment decision in June. Chronos would bring an automated manufacturing line capable of 1 GW annual capacity to ITM’s Sheffield plant, using next-generation electrolysers that triple output and cut production costs by 40%.

Two other processes run in parallel: the results of the UK’s Hydrogen Allocation Round 2, and a potential final investment decision on Uniper’s 120 MW project on the Humber. There is also a cooperation with German defence group Rheinmetall to build a Europe-wide network of synthetic fuel plants for NATO forces — a business area that did not feature in the investment case a year ago.

Cash provides a buffer. With roughly £200m in net liquidity, ITM has more than three years of runway at current spending levels. The balance sheet is strong enough that Jefferies feels comfortable cutting its discount rate assumptions. But a return to profit is still years off, and the forced buying from MSCI index funds later this month will come with no guarantee of staying power. The coming weeks will test whether the stock can hold its gains once the technical buying is done.